| Basics |
| Company: |
Xilio Therapeutics, Inc. Common Stock |
| IPO Date: |
October 18, 2021 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$46.56M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.22 | 5.05%
|
| Avg Daily Range (30 D): |
$0.05 | 4.74%
|
| Avg Daily Range (90 D): |
$0.06 | 5.62%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.38M |
| Avg Daily Volume (30 D): |
5.92M |
| Avg Daily Volume (90 D): |
2.27M |
| Trade Size |
| Avg Trade Size (Sh.): |
325 |
| Avg Trade Size (Sh.) (30 D): |
432 |
| Avg Trade Size (Sh.) (90 D): |
428 |
| Institutional Trades |
| Total Inst.Trades: |
16 |
| Avg Inst. Trade: |
$2.12M |
| Avg Inst. Trade (30 D): |
$.53M |
| Avg Inst. Trade (90 D): |
$.53M |
| Avg Inst. Trade Volume: |
.7M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.69M |
| Avg Closing Trade (30 D): |
$M |
| Avg Closing Trade (90 D): |
$M |
| Avg Closing Volume: |
597.56K |
|
|
|
|
| News |
Feb 10, 2025 @ 3:00 PM
RNA Based Therapeutic Market Size Expected to Reac...
Source: Towards Healthcare
|
Oct 30, 2024 @ 1:01 PM
Xilio Therapeutics to Present Initial Phase 1C Dos...
Source: N/A
|
Jun 13, 2024 @ 8:05 PM
Xilio Therapeutics Appoints Aoife Brennan, M.D., a...
Source: Xilio Therapeutics, Inc.
|
May 14, 2024 @ 11:30 AM
Xilio Therapeutics Announces Pipeline and Business...
Source: Xilio Therapeutics, Inc.
|
Apr 26, 2024 @ 2:24 PM
Gilead (GILD) Q1 Loss Narrower Than Expected, Sale...
Source: Zacks Equity Research
|
| Financials |
| |
TTM |
Q3 2024 |
Q2 2024 |
|
Basic EPS
|
$-1.55
|
$-.22
|
$-.24
|
|
Diluted EPS
|
$-1.55
|
$-.22
|
$-.24
|
|
Revenue
|
$ 4.62M
|
$ 2.26M
|
$ 2.36M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -62.8M
|
$ -14.02M
|
$ -13.93M
|
|
Operating Income / Loss
|
$ -65.08M
|
$ -14.76M
|
$ -14.7M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ 1.68M
|
$ -13.68M
|
$ 30.43M
|
|
PE Ratio
|
|
|
|
|
